New Triple-Drug attack shows promise against tough stomach cancer
NCT ID NCT07176312
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 26 times
Summary
This study tests a combination of three drugs (zanidatamab, pembrolizumab, and chemotherapy) in people with advanced stomach or esophageal cancer that has spread and tests positive for HER2 and PD-L1. The goal is to see if this triple therapy can keep the cancer from growing for at least 12 months. About 80 participants who have not had prior treatment for their advanced disease will receive the combination and be monitored for response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asklepios Klinik Altona
RECRUITINGHamburg, Germany
Contact
-
Charité CVK
NOT_YET_RECRUITINGBerlin, Germany
Contact
-
Evang. Kliniken Essen Mitte
NOT_YET_RECRUITINGEssen, Germany
Contact
-
Hämatologisch Onkologische Praxis Eppendorf (HOPE)
RECRUITINGHamburg, 20249, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johannes Wesling Klinikum Minden
NOT_YET_RECRUITINGMinden, Germany
Contact
-
Klinikum Bielefeld
NOT_YET_RECRUITINGBielefeld, Germany
Contact
-
Klinikum Wolfsburg
NOT_YET_RECRUITINGWolfsburg, Germany
-
Klinikum rechts der Isar der TU München
RECRUITINGMünchen, Germany
-
Krankenhaus Barmherzige Brüder Regensburg
NOT_YET_RECRUITINGRegensburg, Germany
-
Krankenhaus Nordwest
NOT_YET_RECRUITINGFrankfurt, Germany
Contact
-
LMU Klinikum München Großhadern
NOT_YET_RECRUITINGMünchen, Germany
Contact
-
MVZ für Hämatologie und Onkologie Ravensburg
NOT_YET_RECRUITINGRavensburg, Germany
-
St. Anna Hospital Herne
RECRUITINGHerne, Germany
Contact
-
Städtisches Klinikum Dresden
NOT_YET_RECRUITINGDresden, Germany
Contact
-
Universitätsklinikum Göttingen
NOT_YET_RECRUITINGGöttingen, Germany
Contact
-
Universitätsklinikum Hamburg Eppendorf
RECRUITINGHamburg, Germany
Contact
-
Universitätsklinikum Jena
NOT_YET_RECRUITINGJena, Germany
Contact
-
Universitätsklinikum Ulm
RECRUITINGUlm, Germany
Contact
-
Universitätsmedizin Mainz
NOT_YET_RECRUITINGMainz, Germany
Contact
-
Vivantes Klinikum im Friedrichshain
NOT_YET_RECRUITINGBerlin, Germany
Conditions
Explore the condition pages connected to this study.